Why the study?
Does telmisartan increase skeletal muscle fatty acid oxidation compared to other ARBs in rat models of metabolic syndrome?
Does telmisartan increase skeletal muscle fatty acid oxidation compared to other ARBs in rat models of metabolic syndrome?
Telmisartan increases skeletal muscle fatty acid oxidation in rat models of metabolic syndrome through a PPAR-gamma dependent pathway, suggesting a mechanism for its metabolic benefits compared to other ARBs.
No takes yet. Share an insight, caveat, or question.
Telmisartan may enhance skeletal muscle fatty acid oxidation versus losartan in rats; leaves open translation to human metabolic syndrome therapy.
Sugimoto et al. (2008) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: